Green light given for new EudraVigilance system
Management Board endorsement starts countdown for stakeholders to get ready for launch of improved system in November 2017
The European Medicines Agency (EMA) will launch a new and improved version of EudraVigilance, the European information system of suspected adverse reactions to medicines that are authorised or being studied in clinical trials in the European Economic Area (EEA). The new version of EudraVigilance will go live on 22 November 2017 with enhanced functionalities for reporting and analysing suspected adverse reactions.
Recommended to read : PHARMACOVIGILANCE CAREERS & FAQS
Users of the system, i.e. national competent authorities, marketing authorisation holders and sponsors of clinical trials, have to make final preparations to ensure that their processes and local IT infrastructure are compatible with the new system and the internationally agreed format.
An independent audit and a subsequent favourable recommendation from EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded that the updated EudraVigilance system is fully functional. Therefore, pursuant to Article 24(2) third subparagraph of Regulation (EC) No 726/20041, EMA’s Management Board confirmed and announced that the EudraVigilance database has achieved full functionality and the system meets the functional specifications.
The enhancements for reporting and analysing suspected adverse reactions of the new EudraVigilance system will support better safety monitoring of medicines and a more efficient reporting process for stakeholders. Expected benefits include:
- Simplified reporting of individual case safety reports (ICSRs) and the re-routing of ICSRs to Member States as marketing authorisation holders will no longer have to provide these reports to national competent authorities, but directly to EudraVigilance, which will ultimately reduce duplication of efforts. An ICSR provides information on an individual case of a suspected adverse reaction to a medicine;
- Better detection of new or changing safety issues, enabling rapid action to protect public health;
- Increased transparency based on broader access to reports of suspected adverse reactions by healthcare professionals and general public via the adrreports.eu portal, the public interface of the EudraVigilance database;
- Enhanced search and more efficient data analysis capabilities;
- Increased system capacity and performance to support large volumes of users and reports (including non-serious adverse reactions originating from the EEA);
More efficient collaboration with the World Health Organization (WHO) as EMA will make the reports of individual cases of suspected adverse reactions within the EEA available to the WHO Uppsala Monitoring Centre (UMC) directly from EudraVigilance; Member States will no longer need to carry out this task.
For reading complete article : Click Here
Hope Green light given for new EudraVigilance system article is informative on regulatory update. Do share on your circles and network. Provide your valuable feedback in the comments section.